Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

UNCOVERED: 2 - Caught on Camera

Stocks mixed as AstraZeneca merger talk dents FTSE 100

The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.

Evening Standard · Aug 3

AstraZeneca ‘in talks to create £300bn pharmaceutical giant’

IN FULL

The Independent UK · Aug 3

AstraZeneca in talks over £300bn mega-merger with US rival – reports

The move would mark one of the industry’s largest ever deals and create the world’s fourth largest pharmaceutical company.

Evening Standard · Aug 3

From analysis to the latest developments in health,
read the most diverse news in one place.

AstraZeneca share prices drop amid £300bn mega-merger talks with US rival

The merger would mark one of the industry’s largest ever deals and create the world’s fourth largest pharmaceutical company

The Independent UK · Aug 3

AstraZeneca falls to third-largest UK company amid US merger talks

Proposed $400bn tie-up with Bristol Myers Squibb would create world’s fourth-largest drugmaker but analysts question rationale

The Guardian - UK · Aug 3

UK economy faces recession if strait of Hormuz remains closed, EY warns - as it happened

Rolling coverage of the latest economic and financial news

The Guardian - UK · Aug 3

GSK heads to Cambridge with long-awaited positive vibes

Pharmaceutical company’s move to new £400m research centre accompanied by encouraging news for shareholders

The Guardian - UK · Jul 28

Read news from The Economist, FT, and more,
with one subscription

Andhra Pradesh teams up with AstraZeneca for next-gen cancer care model

Andhra Pradesh signed an MoU with AstraZeneca for an integrated precision oncology ecosystem. This initiative will integrate artificial intelligence and advanced genomics for cancer care. The collaboration aims to transform patient journeys from screening to follow-up. AstraZeneca will deploy AI-powered solutions for early lung cancer detection. An Integrated Genomic Solutions…

The Economic Times · Jul 28

AstraZeneca boss urges western drugmakers to move at ‘Chinese speed’

Europe and US risk being outpaced on innovation, as happened in the car industry, warns Pascal Soriot

The Guardian - UK · Jul 27

AstraZeneca quarterly net profit rises 2% on strong cancer drug sales

Strong cancer drug sales lifted Anglo-Swedish pharmaceutical giant AstraZeneca’s second-quarter earnings above expectations, helping the company maintain its 2026 outlook.

Euronews · Jul 27

AstraZeneca sales boosted by soaring demand for cancer treatments

It reported total revenues of 30.67 billion US dollars for the first six months of 2026.

The Independent UK · Jul 27

AstraZeneca sales rise as demand for cancer treatments grow

It reported total revenues of 30.67 billion US dollars for the first six months of 2026.

Evening Standard · Jul 27

Oil price slides as US and Iran pause fire; cancer treatments help AstraZeneca beat profit forecasts – as it happened

Rolling coverage of the latest economic and financial news

The Guardian - UK · Jul 27

Big pharma's patent cliff meets a new biotech Cold War: We need to outrun China, not outlaw it

If we slash federal research budgets, we risk hamstringing our scientists and losing an otherwise winnable race.

Fortune · Jul 24

Get all your
news in one place.

100's of premium titles.
One news app.

The Economic Times · Jul 24

AstraZeneca 'magic' faces rare test after trial failure, share slide

AstraZeneca's nerve drug Wainua unexpectedly failed a late-stage heart disease trial. This setback has caused investor concern and impacted the company's share price. Investors now await results from two key oncology trials, SERENA-4 and AVANZAR. Success in these trials is crucial for maintaining confidence in AstraZeneca's research engine. The company…

The Independent UK · Jul 21

Mother with breast cancer forced to fundraise £200k for life-extending drug due to ‘unfair’ postcode lottery

Breast Cancer drug Enhertu is not available on the NHS in England and costs about £20,000 for three months privately

Medical Daily · Jul 20

FDA Approves Lipfendra, the First Oral PCSK9 Inhibitor: A Once-Daily Pill That Cuts LDL Cholesterol as Well as Injectables

FDA approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor, on July 16, 2026. The once-daily pill cut LDL by up to 59% in trials. Here's who it's for.

The Economic Times · Jul 20

Natco Pharma shares surge 5% after US FDA's tentative nod Olaparib tablets

Natco Pharma shares rose sharply on Monday after the U.S. FDA granted tentative approval for its generic Olaparib tablets, a bioequivalent version of AstraZeneca’s Lynparza. The drug addresses a $1.4-billion U.S. market opportunity. The company will manufacture the product, while Alembic Pharmaceuticals will handle its U.S. commercialisation.

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK · Jul 19

Pay gap widens as UK bosses get 130 times average worker’s salary

In its final report the High Pay Centre says the median remuneration of a FTSE 100 CEO has risen to a record £5.06m

The Economic Times · Jul 19

Alembic Pharma partner NATCO gets USFDA tentative nod for generic Olaparib tablets; US market size at USD 1.4 bn

Alembic Pharmaceuticals and NATCO Pharma received tentative USFDA approval for generic Olaparib tablets. This approval is for a cancer drug, which is a generic equivalent of Lynparza. Alembic will distribute the product while NATCO Pharma will manufacture the tablets. The product addresses a significant market opportunity, estimated at USD 1.4…

The Economic Times · Jul 14

AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical

Dizal Pharmaceutical shares rose significantly after announcing a major drug rights deal. AstraZeneca will pay $600 million upfront for global rights to Sunvozertinib. This targeted treatment addresses a specific genetic mutation in lung cancer patients. The agreement includes potential future payments tied to development and sales. This collaboration aims to…

MarketBeat · Jul 13

The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions

Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.

International Business Times · Jul 9

AstraZeneca Shares Sink After Heart Drug Trial Miss. Rare Clinical Setback Tests Investor Confidence

AstraZeneca shares fell sharply Thursday after the pharmaceutical giant reported that its experimental use of Wainua failed to achieve the primary endpoint in a late-stage clinical trial for a rare heart disease.

Evening Standard · Jul 9

FTSE 100 held back by AstraZeneca trial setback

The FTSE 100 closed down 16.59 points at 10,472.45.

Evening Standard · Jul 9

AstraZeneca sees stock market value slump by more than £20bn after drug setback

The FTSE 100 firm found the Wainua drug failed to meet a goal to reduce deaths related to heart disease.

1 2 3 4 5

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.